October 18, 2018

Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform

Read More
September 26, 2018

Selexis and Hoba Therapeutics Team Up to Advance Hoba’s Investigational Neuropathic Pain Treatment into the Clinic

Read More
September 13, 2018

Meet with Selexis Scientific and Business Leaders at Several Upcoming Industry Conferences and Events

Read More
July 10, 2018

Symphogen A/S and Selexis Expand Relationship as Symphogen Advances its Monoclonal Antibody (mAb) Mixture Pipeline

Read More
June 12, 2018

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer’s Disease

Read More
May 31, 2018

IAVI, Selexis SA and Collaborators Publish Study Highlighting Improved Approach for Generating Complex Proteins Required for Producing HIV Vaccines

Read More
May 17, 2018

Selexis Named One of the “Best Companies to Work for in Switzerland 2018”

Read More
May 07, 2018

Swiss Biotech Association Honors Selexis Among Its Inaugural Group of Swiss Biotech Success Stories

Read More
April 11, 2018

Selexis SA Strengthens Cell Line Development Services for Partners with Key Strategic Hires and Investment in State-of-the-Art Laboratory Equipment

Read More
March 07, 2018

Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics

Read More
February 26, 2018

Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates

Read More
January 17, 2018

Selexis SA Appoints Alberto Garotti as Chief Financial Officer

Read More
January 05, 2018

Selexis SA to Participate at Several Upcoming Industry Conferences

Read More